Your browser is no longer supported. Please, upgrade your browser.
Settings
IONS Ionis Pharmaceuticals, Inc. daily Stock Chart
IONS [NASD]
Ionis Pharmaceuticals, Inc.
Index- P/E84.36 EPS (ttm)0.54 Insider Own0.20% Shs Outstand132.30M Perf Week0.29%
Market Cap5.97B Forward P/E128.94 EPS next Y0.35 Insider Trans-27.55% Shs Float124.58M Perf Month-1.89%
Income67.30M PEG2.11 EPS next Q-0.17 Inst Own87.10% Short Float10.05% Perf Quarter2.31%
Sales555.40M P/S10.75 EPS this Y214.20% Inst Trans0.41% Short Ratio10.66 Perf Half Y3.82%
Book/sh5.41 P/B8.34 EPS next Y156.50% ROA-2.60% Target Price56.42 Perf Year-21.83%
Cash/sh14.97 P/C3.01 EPS next 5Y40.00% ROE-10.10% 52W Range39.07 - 65.51 Perf YTD-10.28%
Dividend- P/FCF11.30 EPS past 5Y26.60% ROI14.60% 52W High-31.11% Beta2.66
Dividend %- Quick Ratio8.30 Sales past 5Y37.80% Gross Margin38.20% 52W Low15.51% ATR1.94
Employees547 Current Ratio8.40 Sales Q/Q13.00% Oper. Margin-8.80% RSI (14)40.72 Volatility4.36% 4.06%
OptionableYes Debt/Eq0.90 EPS Q/Q-246.90% Profit Margin-7.20% Rel Volume0.64 Prev Close45.00
ShortableYes LT Debt/Eq0.90 EarningsNov 06 BMO Payout- Avg Volume1.17M Price45.13
Recom2.80 SMA20-6.88% SMA50-5.85% SMA200-4.67% Volume749,938 Change0.29%
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-08-18Downgrade Evercore ISI Outperform → In-line
Oct-06-17Resumed Goldman Sell $30
Aug-17-17Initiated Evercore ISI Outperform $65
Aug-09-17Reiterated Stifel Hold $42 → $50
Mar-10-17Downgrade Goldman Neutral → Sell
Dec-28-16Reiterated BMO Capital Markets Outperform $61 → $68
Dec-27-16Reiterated Leerink Partners Mkt Perform $40 → $47
Dec-27-16Reiterated Laidlaw Buy $59 → $65
Nov-10-16Resumed Leerink Partners Mkt Perform
Aug-10-16Reiterated Piper Jaffray Overweight $36 → $46
Aug-03-16Initiated Morgan Stanley Equal-Weight $37
Aug-02-16Reiterated Needham Buy $55 → $64
Aug-02-16Reiterated Barclays Equal Weight $26 → $41
May-27-16Reiterated Needham Buy $88 → $55
Oct-11-18 07:00AM  Here's Why Ionis Pharmaceuticals Rose 12.9% in September Motley Fool
Oct-10-18 10:12AM  [$$] Ionis, Roche Reach New Collaboration Agreement The Wall Street Journal
09:27AM  Ionis's stock surges after Roche collaboration, which could be worth up to $759 million MarketWatch
09:07AM  Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases PR Newswire
Oct-08-18 07:00AM  Akcea Announces Changes to Board of Directors GlobeNewswire -7.65%
Oct-05-18 07:11PM  Cambridge's Akcea rebounds with FDA approval of first drug American City Business Journals
06:17PM  Akcea Therapeutics genetic disease treatment gets FDA approval Reuters
05:33PM  Akcea Announces Its Access and Distribution Strategy for TEGSEDI (inotersen) GlobeNewswire
05:32PM  Akcea and Ionis Receive FDA Approval of TEGSEDI (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults GlobeNewswire
Sep-27-18 09:32AM  When Will Ionis Pharmaceuticals Inc (NASDAQ:IONS) Become Profitable? Simply Wall St.
Sep-24-18 04:06PM  Ionis Announces the Appointment of Two New Board Members PR Newswire
Aug-29-18 09:23AM  Can Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. Recover? Motley Fool
07:35AM  3 Big Stock Charts for Wednesday: PG&E, PepsiCo and Hewlett Packard Enterprise InvestorPlace
07:09AM  Ionis stock drops 13% as FDA fails to approve key drug MarketWatch
07:00AM  Ionis Pharmaceuticals to Present at Upcoming Investor Conferences PR Newswire
Aug-28-18 04:34PM  Why Canopy Growth, Mitek Systems, and Ionis Pharmaceuticals Slumped Today Motley Fool -15.88%
12:51PM  Here's Why Ionis Pharmaceuticals and Akcea Therapeutics Plummeted Today Motley Fool
10:24AM  Akcea Plunges as Analysts Fear Wider Fallout From Drug Setback Bloomberg
08:45AM  Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session Zacks
08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 05:47PM  After-hours buzz: AMD, AKCA, IONS & more CNBC +7.83%
05:30PM  FDA rejects rare disease drug developed by Cambridge's Akcea American City Business Journals
05:07PM  Akcea, Ionis shares drop after disappointing FDA decision MarketWatch
05:01PM  What Happened in the Stock Market Today Motley Fool
04:39PM  U.S. FDA declines to approve Akcea/Ionis genetic disease drug Reuters
04:30PM  Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA GlobeNewswire
02:59PM  Pfizer Slips Despite Mostly Positive Tafamidis Data; 4 Pharma Stocks Make Sympathy Moves Benzinga
01:07PM  Here's Why Alnylam Pharmaceuticals and Ionis Pharmaceuticals Jumped Today Motley Fool
08:38AM  Pfizer rare-disease drug results lift its shares and those of rival MarketWatch
Aug-23-18 10:02AM  Recent Analysis Shows Fitbit, Southwestern Energy, DAQO New Energy, ANGI Homeservices, Inc., Ionis Pharmaceuticals, and Cronos Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-22-18 03:52PM  Should Alnylam's and Ionis' Investors Be Worried About This Recent IPO? Motley Fool
Aug-20-18 11:59PM  Edited Transcript of IONS earnings conference call or presentation 7-Aug-18 3:30pm GMT Thomson Reuters StreetEvents
08:00AM  3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro Motley Fool
Aug-17-18 10:02PM  Heres Why Alnylams Shares Are Tumbling Motley Fool
Aug-16-18 06:06PM  UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven classes of UBS 2017-C3 Moody's
Aug-15-18 01:41PM  Akcea Therapeutics Soars as It Readies Its First Drug Launch Motley Fool
Aug-13-18 01:36PM  Ionis Pharmaceuticals' Royalties Rise, but So Do Expenses Motley Fool
08:17AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Aug-11-18 02:30PM  Why Biogen's Stock Ripped Higher in July Motley Fool
Aug-09-18 01:29PM  Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript Motley Fool +5.79%
Aug-07-18 11:25AM  Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates Zacks
10:20AM  Ionis Pharmaceuticals: 2Q Earnings Snapshot Associated Press
09:37AM  Ionis (IONS) Posts Wider than Expected Loss in Q2, Sales Miss Zacks
09:30AM  Ionis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Ionis Reports Second Quarter 2018 Financial Results PR Newswire
Aug-06-18 04:05PM  Akcea Reports Financial Results and Highlights for Second Quarter 2018 GlobeNewswire
01:09PM  Alnylam Pharmaceuticals Is "Launch Ready" Motley Fool
Aug-03-18 02:46PM  Avoid Treating Biogen Like a Speculative Drug Stock InvestorPlace
Aug-02-18 04:05PM  IONIS-HTT Rx (RG6042) Granted PRIME Designation by the European Medicines Agency for the Treatment of People with Huntington's Disease PR Newswire
08:00AM  Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America PR Newswire
Aug-01-18 12:18PM  Is a Beat in Store for Ionis (IONS) This Earnings Season? Zacks
Jul-25-18 03:21PM  Biogen Posts Solid Earnings as the Biotech Waits for Clinical Trial Data Motley Fool
11:12AM  Why Every Investor Should Hold Shares of Biogen Stock InvestorPlace
Jul-24-18 07:00AM  Ionis Pharmaceuticals to Hold Second Quarter 2018 Financial Results Webcast PR Newswire
Jul-23-18 04:30PM  Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast GlobeNewswire
Jul-18-18 08:08AM  Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates Zacks
Jul-12-18 09:21AM  Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer Zacks
08:46AM  Is Ionis Pharmaceuticals, Inc. a Buy? Motley Fool
Jul-11-18 08:41AM  Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8% Zacks
07:31AM  Akcea and Ionis Announce Approval of TEGSEDI(TM) (inotersen) in the European Union GlobeNewswire
07:30AM  Akcea and Ionis Announce Approval of TEGSEDI (inotersen) in the European Union GlobeNewswire
07:20AM  Free Technical Research on Intrexon and Three More Biotech Equities ACCESSWIRE
Jul-09-18 08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals ACCESSWIRE
Jul-06-18 04:00AM  [$$] Dynacure Pumps War Chest to Beat Rare Muscle Diseases The Wall Street Journal
Jul-05-18 04:27PM  Why This Biotech Company 'Dominates' Its Rival In Drug Study Investor's Business Daily
07:00AM  New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI (inotersen) for the Treatment of Hereditary ATTR Amyloidosis PR Newswire
Jun-20-18 03:35PM  Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs Investor's Business Daily
08:00AM  Don't Get Too Excited About PTC Therapeutics (Yet) Motley Fool
Jun-18-18 09:25PM  How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)? Simply Wall St. -6.37%
01:15PM  Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle Motley Fool
07:00AM  Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer PR Newswire
Jun-13-18 07:35AM  Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis Pharmaceuticals, and Photronics What Drives Growth in Today's Competitive Landscape GlobeNewswire
07:31AM  Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference GlobeNewswire
07:01AM  Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS GlobeNewswire
07:00AM  Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS GlobeNewswire
Jun-11-18 01:29PM  Biogen Buys $625 Million in Ionis Stock Barrons.com
Jun-05-18 04:00PM  Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases PR Newswire
Jun-04-18 11:36AM  3 Top Biotech Stocks to Buy in June Motley Fool
Jun-03-18 07:18AM  Better Buy: Biogen Inc. vs. Celgene Motley Fool
Jun-01-18 10:13AM  Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI GlobeNewswire
08:07AM  Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI GlobeNewswire
May-23-18 07:00AM  Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders PR Newswire
May-20-18 04:38PM  Uniqure Notches Bullish Initiation On Gene Therapy Prospects Benzinga
May-19-18 09:12AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-11-18 12:13PM  Why Akcea Therapeutics Rocketed Higher Today Motley Fool +7.36%
09:53AM  Akcea and Ionis Just Got A Major Boost Market Exclusive
May-10-18 06:21PM  FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome GlobeNewswire
May-09-18 04:11PM  Ionis Pharmaceuticals Prepares for Launch Motley Fool +5.61%
03:58AM  Edited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMT Thomson Reuters StreetEvents
May-07-18 05:07PM  Ionis Pharmaceuticals (IONS) Q1 2018 Earnings Conference Call Transcript Motley Fool
May-04-18 01:16PM  10 Ionis Pharmaceuticals Inc Earnings Highlights InvestorPlace +6.64%
08:01AM  Ionis (IONS) Beats Earnings & Misses Revenues in Q1 Zacks
07:44AM  Ionis Pharma shares lift 4% after Q1 profit, revenue beats MarketWatch
07:21AM  Ionis Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Ionis Reports First Quarter 2018 Financial Results PR Newswire
May-01-18 10:41AM  What's in the Cards for Ionis (IONS) This Earnings Season? Zacks
Apr-30-18 07:01PM  Cramer's lightning round: Corning's stock is an unnecessa... CNBC Videos
04:26PM  Biogen's $1 Billion Bet on Ionis Motley Fool
Apr-28-18 06:27PM  Is Biogen Inc. a Buy? Motley Fool
Apr-26-18 06:40PM  A Promising Step for Medical Marijuana Motley Fool
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases; Roche to develop therapeutics for the treatment of complement-mediated diseases; and drug research collaboration with SRI International for the intracellular delivery of nucleic acid-based drugs, as well as a research collaboration agreement with Cerveau Technologies, Inc. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Monia Brett PChief Operating OfficerAug 27Option Exercise7.2316,493119,27424,834Aug 29 04:49 PM
Monia Brett PChief Operating OfficerAug 27Sale54.0016,493890,62215,841Aug 29 04:49 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Option Exercise14.6812,500183,52831,883Aug 09 06:34 PM
BENNETT C FRANKSVP, Antisense ResearchAug 08Sale45.0012,500562,50019,396Aug 09 06:34 PM
Monia Brett PChief Operating OfficerJul 24Sale47.031567,33715,841Jul 25 07:19 PM
WENDER JOSEPH HDirectorJul 17Option Exercise9.2630,000277,80068,916Jul 19 06:45 PM
LOSCALZO JOSEPHDirectorJul 03Option Exercise0.00667010,419Jul 03 03:20 PM
Castleman BreauxDirectorJul 03Option Exercise0.00667012,294Jul 03 03:13 PM
WENDER JOSEPH HDirectorJul 03Option Exercise0.00667038,916Jul 03 03:10 PM
BERTHELSEN SPENCER RDirectorJul 03Option Exercise0.00667094,094Jul 03 03:08 PM
KLEIN JOSEPH IIIDirectorJul 03Option Exercise0.00667012,606Jul 03 03:07 PM
LOSCALZO JOSEPHDirectorJul 01Option Exercise0.002,00009,752Jul 03 03:20 PM
Castleman BreauxDirectorJul 01Option Exercise0.002,000011,627Jul 03 03:13 PM
WENDER JOSEPH HDirectorJul 01Option Exercise0.002,000038,249Jul 03 03:10 PM
BERTHELSEN SPENCER RDirectorJul 01Option Exercise0.002,000093,427Jul 03 03:08 PM
KLEIN JOSEPH IIIDirectorJul 01Option Exercise0.002,000011,939Jul 03 03:07 PM
BERTHELSEN SPENCER RDirectorJun 25Option Exercise13.8815,000208,200100,727Jun 25 08:28 PM
BERTHELSEN SPENCER RDirectorJun 25Sale42.3015,000634,54291,427Jun 25 08:28 PM
MUTO FREDERICK TDirectorMay 31Option Exercise13.8815,000208,20022,127May 31 08:02 PM
MUTO FREDERICK TDirectorMay 31Sale46.4515,000696,7507,127May 31 08:02 PM
WENDER JOSEPH HDirectorMay 11Option Exercise13.8815,000208,20044,839May 11 09:00 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Option Exercise7.2512,50090,62531,614May 11 09:06 PM
BENNETT C FRANKSVP, Antisense ResearchMay 11Sale45.0012,500562,50019,114May 11 09:06 PM
WENDER JOSEPH HDirectorMay 11Sale45.3115,000679,61436,249May 11 09:00 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise10.824,00043,2806,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Option Exercise14.699,962146,34256,714Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.404,000177,6004,128Apr 19 05:22 PM
CROOKE STANLEY TChairman and CEOApr 17Sale44.409,962442,31351,733Apr 19 05:22 PM
KLEIN JOSEPH IIIDirectorMar 29Option Exercise24.422,00048,84011,939Mar 30 03:51 PM
KLEIN JOSEPH IIIDirectorMar 29Sale46.152,00092,3009,939Mar 30 03:51 PM
KLEIN JOSEPH IIIDirectorMar 15Option Exercise24.422,00048,84010,839Mar 16 04:19 PM
KLEIN JOSEPH IIIDirectorMar 15Sale51.132,000102,2589,939Mar 16 04:19 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 12Option Exercise10.821,00010,82015,452Mar 13 09:14 PM
O'NEIL PATRICK R.SVP Legal & General CounselMar 12Sale55.001,00055,00014,452Mar 13 09:14 PM
KLEIN JOSEPH IIIDirectorFeb 28Option Exercise35.533,000106,59012,039Mar 01 05:52 PM
KLEIN JOSEPH IIIDirectorFeb 28Sale51.913,000155,7279,939Mar 01 05:52 PM
KLEIN JOSEPH IIIDirectorFeb 15Option Exercise35.533,000106,59011,539Feb 16 06:00 PM
KLEIN JOSEPH IIIDirectorFeb 15Sale48.993,000146,9849,939Feb 16 06:00 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 29Option Exercise10.823553,84114,752Jan 31 04:16 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 29Sale55.0035519,52514,452Jan 31 04:16 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 25Option Exercise10.826456,97915,097Jan 29 04:08 PM
O'NEIL PATRICK R.SVP Legal & General CounselJan 25Sale55.0064535,47514,452Jan 29 04:08 PM
KLEIN JOSEPH IIIDirectorJan 16Option Exercise35.533,000106,59011,539Jan 17 09:28 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 16Sale51.762,724140,99414,500Jan 17 09:46 PM
Geary Richard SSVP, DevelopmentJan 16Sale51.762,723140,94216,680Jan 17 09:26 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 16Sale51.762,697139,59714,452Jan 17 09:25 PM
PARSHALL B LYNNEDirectorJan 16Sale51.765,986309,83538,180Jan 17 09:25 PM
Boyce SarahChief Business OfficerJan 16Sale51.762,196113,6658,931Jan 17 09:23 PM
BENNETT C FRANKSVP, Antisense ResearchJan 16Sale51.762,696139,54519,114Jan 17 09:22 PM
Monia Brett PCOOJan 16Sale51.762,821146,01515,783Jan 17 09:21 PM
KLEIN JOSEPH IIIDirectorJan 16Sale52.523,000157,5669,939Jan 17 09:28 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.001,72204,784Jan 17 09:22 PM
CROOKE STANLEY TChairman and CEOJan 15Option Exercise0.0029,612067,626Jan 17 09:22 PM
Monia Brett PCOOJan 15Option Exercise0.006,985018,604Jan 17 09:21 PM
HOUGEN ELIZABETH LSVP, Finance & CFOJan 15Option Exercise0.006,732017,224Jan 17 09:46 PM
Geary Richard SSVP, DevelopmentJan 15Option Exercise0.006,732019,403Jan 17 09:26 PM
O'NEIL PATRICK R.SVP, Legal & General CounselJan 15Option Exercise0.006,663017,149Jan 17 09:25 PM
PARSHALL B LYNNEDirectorJan 15Option Exercise0.0018,339044,166Jan 17 09:25 PM
Boyce SarahChief Business OfficerJan 15Option Exercise0.005,367011,127Jan 17 09:23 PM
BENNETT C FRANKSVP, Antisense ResearchJan 15Option Exercise0.006,663021,810Jan 17 09:22 PM
CROOKE STANLEY TChairman and CEOJan 15Sale51.7665633,9554,128Jan 17 09:22 PM
CROOKE STANLEY TChairman and CEOJan 15Sale51.7615,893822,62251,733Jan 17 09:22 PM
CROOKE STANLEY TChairman and CEOJan 08Option Exercise10.821,00010,8204,062Jan 10 06:43 PM
CROOKE STANLEY TChairman and CEOJan 08Option Exercise14.6910,000146,90048,014Jan 10 06:43 PM
CROOKE STANLEY TChairman and CEOJan 08Sale52.011,00052,0103,062Jan 10 06:43 PM
CROOKE STANLEY TChairman and CEOJan 08Sale52.0110,000520,10038,014Jan 10 06:43 PM
CROOKE STANLEY TChairman and CEOJan 03Option Exercise9.212,00018,4134,158Jan 05 04:41 PM
CROOKE STANLEY TChairman and CEOJan 03Option Exercise14.6920,000293,80058,014Jan 05 04:41 PM
CROOKE STANLEY TChairman and CEOJan 03Sale49.882,00099,7603,062Jan 05 04:41 PM
CROOKE STANLEY TChairman and CEOJan 03Sale50.0220,0001,000,40038,014Jan 05 04:41 PM
Monia Brett PSVP, Antisense Drug DiscoveryJan 02Sale50.001638,15011,619Jan 02 08:49 PM
KLEIN JOSEPH IIIDirectorDec 29Option Exercise28.473,00085,41012,939Jan 02 05:50 PM
KLEIN JOSEPH IIIDirectorDec 29Sale50.563,000151,6809,939Jan 02 05:50 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 15Option Exercise10.295,00051,45015,392Dec 19 08:20 PM
KLEIN JOSEPH IIIDirectorDec 15Option Exercise28.473,00085,41012,939Dec 19 08:27 PM
KLEIN JOSEPH IIIDirectorDec 15Sale51.693,000155,0709,939Dec 19 08:27 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 15Sale52.555,000262,75010,392Dec 19 08:20 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Option Exercise10.294,00041,16014,392Dec 06 06:36 PM
HOUGEN ELIZABETH LSVP, Finance & CFODec 04Sale57.004,000228,00010,392Dec 06 06:36 PM
O'NEIL PATRICK R.SVP, Legal & General CounselDec 01Option Exercise10.821,00010,82011,433Dec 01 07:03 PM
O'NEIL PATRICK R.SVP, Legal & General CounselDec 01Sale55.501,00055,50010,433Dec 01 07:03 PM
KLEIN JOSEPH IIIDirectorNov 30Option Exercise28.473,00085,41012,939Dec 01 07:04 PM
KLEIN JOSEPH IIIDirectorNov 30Sale53.553,000160,6509,939Dec 01 07:04 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 29Option Exercise10.296,00061,74016,392Dec 01 07:12 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 29Sale53.026,000318,12010,392Dec 01 07:12 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 16Option Exercise10.297,00072,03017,392Nov 17 05:57 PM
KLEIN JOSEPH IIIDirectorNov 16Option Exercise12.942,81236,3879,939Nov 17 05:57 PM
HOUGEN ELIZABETH LSVP, Finance & CFONov 16Sale54.357,000380,45010,392Nov 17 05:57 PM
KLEIN JOSEPH IIIDirectorNov 15Option Exercise28.472,25064,0589,377Nov 17 05:57 PM
KLEIN JOSEPH IIIDirectorNov 15Sale53.562,250120,5107,127Nov 17 05:57 PM
KLEIN JOSEPH IIIDirectorNov 13Sale55.393,000166,1707,127Nov 14 06:29 PM
O'NEIL PATRICK R.SVP, Legal & General CounselNov 01Option Exercise10.821,00010,82011,433Nov 03 05:20 PM
O'NEIL PATRICK R.SVP, Legal & General CounselNov 01Sale58.351,00058,35010,433Nov 03 05:20 PM
BENNETT C FRANKSVP, Antisense ResearchOct 18Option Exercise10.2912,250126,05327,291Oct 20 05:35 PM
PARSHALL B LYNNECOOOct 18Option Exercise27.7116,118446,59834,074Oct 20 05:34 PM
PARSHALL B LYNNECOOOct 18Sale65.0016,1181,047,67025,741Oct 20 05:34 PM
BENNETT C FRANKSVP, Antisense ResearchOct 18Sale65.0012,250796,25015,041Oct 20 05:35 PM